Premium
Blood pressure and heart rate measures: How well do pre‐clinical models translate? (681.7)
Author(s) -
SteidlNichols Jill,
Bhatt Siddhartha,
Hemkens Michelle,
Heyen Jon,
Marshall Catherine,
Li Dingzhou,
Flynn Declan,
Wisialowski Todd,
Northcott Carrie
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.681.7
Subject(s) - safety pharmacology , clinical trial , medicine , blood pressure , heart rate , disease , animal studies , animal model , animal species , translational research , bioinformatics , intensive care medicine , pharmacology , pathology , biology , drug , zoology
Within research, animal models are commonly used to examine the physiology of disease, and evaluate the efficacy and safety of drugs. However, understanding of the translation of cardiovascular (CV) endpoints [specifically, heart rate (HR) and blood pressure (BP)] from pre‐clinical animal studies to the clinic is still limited. Internal databases containing BP and HR data from a broad range of compounds evaluated in pre‐clinical CV safety pharmacology animal models and Phase 1 human clinical trials were used to evaluate the translation across pre‐clinical findings from rodent (rat) to large animal (non human primate and dog), as well as the translation of findings from pre‐clinical animal models to humans. The database currently consists of >700 historical preclinical CV safety pharmacology studies and represents experiments across 5 species. The analysis of this information has indicated that many mechanisms modulate blood pressure and heart rate, further demonstrating the complexity of CV system. Moreover, the data from this wide range of compounds and mechanisms translates across species and also into the clinic, confirming the importance of pre‐clinical animal models in the examination of the efficacy and safety of drugs, and the usefulness of these models for selection of compounds for advancement to clinical testing and ultimately the treatment of disease.